Table 1. Relationship between YKL-40 scores and clinical–pathological factors.
|
No. of YKL-40 scoresa (%)
|
|||||
|---|---|---|---|---|---|
| Factor | No. (%) | Low | Medium | High | P |
| Age (years) | 0.647 | ||||
| <40 | 13 (6.4) | 7 (53.8) | 1 (7.7) | 5 (38.5) | |
| 40–49 | 43 (21.2) | 27 (62.8) | 10 (23.5) | 6 (13.9) | |
| 50–59 | 55 (27.1) | 33 (60) | 11 (20) | 11 (20) | |
| >60 | 92 (45.3) | 54 (58.7) | 17 (18.5) | 21 (22.8) | |
| Total | 203 (100) | 121 (59.6) | 39 (19.2) | 43 (21.2) | |
| Histological subtype | 0.058 | ||||
| Ductal carcinoma | 165 (81.3) | 90 (54.5) | 34 (20.6) | 41 (24.8) | |
| Lobular carcinoma | 25 (12.3) | 20 (80) | 4 (16) | 1 (4) | |
| Medullar carcinoma | 1 (0.5) | 1 (100) | 0 | 0 | |
| Other | 12 (5.9) | 10 (83.3) | 1 (8.3) | 1 (8.3) | |
| Tumour stage | 0.554 | ||||
| I | 92 (45.3) | 58 (63) | 19 (20.6) | 15 (16.3) | |
| II | 89 (43.8) | 51 (57.3) | 16 (17.9) | 22 (24.7) | |
| III | 19 (9.4) | 9 (47.3) | 4 (21) | 6 (31.6) | |
| Unknown | 3 (1.4) | 3 (100) | 0 | 0 | |
| Tumour size (cm) | 0.407 | ||||
| <2 | 84 (41.4) | 55 (65.5) | 15 (17.9) | 14 (16.7) | |
| 2–5 | 102 (50.2) | 58 (56.9) | 21 (20.6) | 23 (22.5) | |
| >5 | 15 (7.4) | 6 (40) | 3 (20) | 6 (40) | |
| Unknown | 2 (1) | 2 (1.6) | 0 | 0 | |
| Tumour grade | <0.0001* | ||||
| I | 27 (13.3) | 22 (81.5) | 3 (11.1) | 2 (7.4) | |
| II | 74 (36.5) | 61 (82.4) | 10 (13.5) | 3 (4) | |
| III | 95 (46.8) | 34 (35.8) | 25 (26.3) | 36 (37.9) | |
| Unknown | 7 (3.4) | 4 (57.1) | 1 (14.3) | 2 (25.6) | |
| Her2/neu | 0.010* | ||||
| Low | 37 (18.2) | 24 (64.9) | 8 (21.6) | 5 (13.5) | |
| Medium | 43 (21.2) | 34 (79) | 7 (16.3) | 2 (4.6) | |
| High | 43 (21.2) | 23 (53.5) | 7 (16.3) | 13 (30.2) | |
| Unknown | 80 (39.4) | 40 (50) | 17 (22.2) | 23 (28.7) | |
| ER status | <0.0001* | ||||
| Positive | 128 (63) | 94 (73.4) | 21 (16.4) | 13 (10.1) | |
| Negative | 59 (29) | 18 (30.5) | 16 (27.1) | 25 (42.4) | |
| Unknown | 16 (7.9) | 9 (56) | 2 (12.5) | 5 (31.2) | |
| PR status | <0.0001* | ||||
| Positive | 101 (49.7) | 78 (77.2) | 10 (9.9) | 13 (12.9) | |
| Negative | 84 (41.4) | 32 (38.1) | 27 (32.1) | 25 (29.8) | |
| Unknown | 18 (8.9) | 11(61.1) | 2 (11.1) | 5 (27.7) | |
| Node status | 0.122 | ||||
| Positive | 81 (35.2) | 48 (59.2) | 15 (18.5) | 18 (22.2) | |
| Negative | 111 (54.7) | 64 (57.6) | 22 (19.8) | 25 (22.5) | |
| Unknown | 11 (5.4) | 11 (100) | 0 | 0 | |
| Distant metastasis b | 0.613 | ||||
| Positive | 41 (20.2) | 24 (58.5) | 11 (26.8) | 6 (14.6) | |
| Negative | 93 (45.8) | 52 (55.9) | 16 (17.2) | 22 (23.6) | |
| Unknown | 69 (34) | 42 (60.9) | 12 (17.4) | 15 (21.7) | |
Abbreviations: ER=oestrogen receptor; PR=progesterone receptor.
a
YKL-40 low, medium, and high scores from combined intensity and density analysis are 0–2, 3–4, and 5–6 points, respectively.
b
The status of metastasis was derived from diagnostic imaging tests as described in Materials and methods, in which negative stands for no metastasis identified in distant organs and unknown indicates no these tests were performed. *P<0.05.